This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

This study has been completed.
Information provided by:
Leiden University Medical Center Identifier:
First received: April 22, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
The purpose of this study is to assess whether therapy with Sorafenib reinduces radioiodine uptake in thyroid carcinoma.

Condition Intervention Phase
Thyroid Cancer Drug: Sorafenib (nexavar) Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

Resource links provided by NLM:

Further study details as provided by Leiden University Medical Center:

Primary Outcome Measures:
  • Proportion of patients with a favorable response to Sorafenib defined as ONE OR MORE of the following criteria: 1. Reinduction of RaI uptake by RaI scintigraphy. 2. Serum thyroglobulin levels. 3. RECIST criteria [ Time Frame: 6 months ]

Enrollment: 32
Study Start Date: October 2007
Arms Assigned Interventions
Experimental: sorafenib
30 patients with non-radioiodine avid differentiated thyroid carcinoma
Drug: Sorafenib (nexavar)
6 months therapy with Sorafenib 800 mg/day
Other Name: nexavar

  Show Detailed Description


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with non-medullary thyroid carcinoma
  • The patients must have undergone total thyroidectomy
  • Presence of metastases or inoperable recurrent disease, as proven by elevated serum thyroglobulin levels (Tg) in combination with radiological evidence for tumor
  • No or insufficient RaI uptake in tumor as proven by RaI scintigraphy, performed after prior RaI therapy

Exclusion Criteria:

  • Pregnancy
  • Other active malignancies
  • Active kidney, liver or pancreatic disease or dysfunction
  • Unstable angina pectoris or recent (<3 months) myocardial infarction.
  • Coagulopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00887107

Leiden University Medical Center
Leiden, Netherlands, 2300 RC
Sponsors and Collaborators
Leiden University Medical Center
Principal Investigator: Johannes W Smit, MD, PhD Leiden Universty Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Johannes Smit, M.D., Ph.D., leiden University Medical Center Identifier: NCT00887107     History of Changes
Other Study ID Numbers: NL17727.058.07
Study First Received: April 22, 2009
Last Updated: April 22, 2009

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on September 21, 2017